{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:57:33Z","timestamp":1768924653446,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00210-021-02169-0","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:56:55Z","timestamp":1634752615000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association and pharmacological synergism of the triple drug therapy baricitinib\/remdesivir\/rhACE2 for the management of COVID-19 infection"],"prefix":"10.1007","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"2169_CR1","doi-asserted-by":"publisher","first-page":"e00221-18","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18","journal-title":"mBio"},{"key":"2169_CR2","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 34:101615. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101615","journal-title":"Travel Med Infect Dis"},{"issue":"19","key":"2169_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez-de-Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, F\u00e4tkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members (2020) Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med 383(19):1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"issue":"4","key":"2169_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/diagnostics11040698","volume":"11","author":"M Di Domenico","year":"2021","unstructured":"Di Domenico M, De Rosa A, Boccellino M (2021) Detection of SARS-COV-2 proteins using an ELISA test. Diagnostics (basel) 11(4):698. https:\/\/doi.org\/10.3390\/diagnostics11040698","journal-title":"Diagnostics (basel)"},{"issue":"Doc04","key":"2169_CR5","first-page":"20","volume":"5","author":"S Duwe","year":"2017","unstructured":"Duwe S (2017a) Influenza viruses - antiviral therapy and resistance. GMS Infect Dis 5(Doc04):20","journal-title":"GMS Infect Dis"},{"key":"2169_CR6","unstructured":"Duwe S (2017b) Influenza viruses - antiviral therapy and resistance. GMS Infect Dis 5, Doc04"},{"issue":"9","key":"2169_CR7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","volume":"20","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Biggioggero M, Maioli G, Caporali R (2020) Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 20(9):1012\u20131013. https:\/\/doi.org\/10.1016\/S1473-3099(20)30262-0","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2169_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4081\/itjm.2020.1290","volume":"14","author":"F Ferrara","year":"2020","unstructured":"Ferrara F (2020) Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med 14(2):114\u2013115. https:\/\/doi.org\/10.4081\/itjm.2020.1290","journal-title":"Ital J Med"},{"key":"2169_CR9","doi-asserted-by":"publisher","unstructured":"Ferrara F, Vitiello A (2020) Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med (AOP) https:\/\/doi.org\/10.4081\/itjm.2020.1435","DOI":"10.4081\/itjm.2020.1435"},{"issue":"5","key":"2169_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/ijp.IJP_417_20","volume":"52","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Porta R, Santilli P, D\u2019Aiuto V, Vitiello A (2020a) Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol 52(5):441\u2013442. https:\/\/doi.org\/10.4103\/ijp.IJP_417_20","journal-title":"Indian J Pharmacol"},{"issue":"11","key":"2169_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","volume":"76","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A (2020b) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 76(11):1615\u20131618. https:\/\/doi.org\/10.1007\/s00228-020-02947-4","journal-title":"Eur J Clin Pharmacol"},{"key":"2169_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02401-5","volume":"17","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Porta R, D\u2019Aiuto V, Vitiello A (2020c) Remdesivir and COVID-19. Ir J Med Sci 17:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02401-5","journal-title":"Ir J Med Sci"},{"key":"2169_CR13","doi-asserted-by":"publisher","unstructured":"Ferrara F, Vitiello A Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn-Schmiedeberg\u2019s Arch Pharmacol Accepted: 6 January 2021. https:\/\/doi.org\/10.1007\/s00210-021-02049-7","DOI":"10.1007\/s00210-021-02049-7"},{"issue":"4","key":"2169_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1871528113666140713164506","volume":"13","author":"RR Gaddam","year":"2014","unstructured":"Gaddam RR, Chambers S, Bhatia M (2014) ACE and ACE2 in inflammation: a tale of two enzymes. Inflamm Allergy Drug Targets 13(4):224\u2013234. https:\/\/doi.org\/10.2174\/1871528113666140713164506","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2169_CR15","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1002\/hep.22900","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Doo EC (2009) Antiviral resistance and hepatitis B therapy. Hepatol Baltim Md 49:S174-184","journal-title":"Hepatol Baltim Md"},{"key":"2169_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.07.937862","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE et al (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses \u2013 a statement of the Coronavirus Study Group. Microbiology. https:\/\/doi.org\/10.1101\/2020.02.07.937862","journal-title":"Microbiology"},{"key":"2169_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ajcp\/aqaa029","volume":"153","author":"J Guarner","year":"2020","unstructured":"Guarner J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153:420\u2013421","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2169_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","volume":"184","author":"TN Hoang","year":"2021","unstructured":"Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Nekorchuk M, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MYH, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Filev PD, Weiskopf D, Silvestri G, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184(2):460-475.e21. https:\/\/doi.org\/10.1016\/j.cell.2020.11.007","journal-title":"Cell"},{"issue":"2020","key":"2169_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(2020):497\u2013506","journal-title":"Lancet"},{"issue":"8","key":"2169_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Tse CLY, Burry L, Dresser LD (2020) Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 40(8):843\u2013856. https:\/\/doi.org\/10.1002\/phar.2438","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2169_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Kebriaei R, Dresser LD (2020) Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40(7):659\u2013671. https:\/\/doi.org\/10.1002\/phar.2429","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2169_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH, ACTT-2 Study Group Members (2021) Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"key":"2169_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"key":"2169_CR24","doi-asserted-by":"publisher","unstructured":"Marconi VC et al (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Published: September 01, 2021. https:\/\/doi.org\/10.1016\/S2213-2600(21)00331-3","DOI":"10.1016\/S2213-2600(21)00331-3"},{"issue":"11","key":"2169_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2020.16337","volume":"324","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Angus DC (2020) Efficacy of remdesivir in COVID-19. JAMA 324(11):1041\u20131042. https:\/\/doi.org\/10.1001\/jama.2020.16337","journal-title":"JAMA"},{"issue":"4","key":"2169_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905-913.e7. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell"},{"issue":"1","key":"2169_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013426","volume":"13","author":"V Monteil","year":"2021","unstructured":"Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, Zhang H, Slutsky AS, Hurtado Del Pozo C, Horn M, Montserrat N, Penninger JM, Mirazimi A (2021) Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med 13(1):e13426. https:\/\/doi.org\/10.15252\/emmm.202013426","journal-title":"EMBO Mol Med"},{"key":"2169_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-020-00407-9","volume":"22","author":"S Muslim","year":"2020","unstructured":"Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, Mustafa G (2020a) Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE2, angiotensin (1\u20137) and angiotensin (1\u20139) as effective therapeutic measure. SN Compr Clin Med 22:1\u20136. https:\/\/doi.org\/10.1007\/s42399-020-00407-9","journal-title":"SN Compr Clin Med"},{"key":"2169_CR29","doi-asserted-by":"publisher","unstructured":"Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, Mustafa G (2020) Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE2, angiotensin (1\u20137) and angiotensin (1\u20139) as effective therapeutic measure. SN Compr Clin Med 1\u20136. https:\/\/doi.org\/10.1007\/s42399-020-00407-9","DOI":"10.1007\/s42399-020-00407-9"},{"key":"2169_CR30","doi-asserted-by":"publisher","unstructured":"Szemiel AM et al (2021) In vitro evolution of remdesivir resistance reveals genome plasticity of SARS-CoV-2. bioRxiv preprint. https:\/\/doi.org\/10.1101\/2021.02.01.429199v1. https:\/\/www.biorxiv.org\/content\/. Accessed August 2021","DOI":"10.1101\/2021.02.01.429199v1"},{"key":"2169_CR31","doi-asserted-by":"publisher","unstructured":"Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O\u2019Shea J, DeSilva K, Chan B, Edwards A, Gavegnano C, Schinazi RF, Marconi VC (2020) Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis ciaa879. https:\/\/doi.org\/10.1093\/cid\/ciaa879","DOI":"10.1093\/cid\/ciaa879"},{"issue":"883","key":"2169_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173373","volume":"15","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020a) Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know? Eur J Pharmacol 15(883):173373. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173373","journal-title":"Eur J Pharmacol"},{"issue":"262","key":"2169_CR33","doi-asserted-by":"publisher","first-page":"118510","DOI":"10.1016\/j.lfs.2020.118510","volume":"1","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020b) Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 1(262):118510. https:\/\/doi.org\/10.1016\/j.lfs.2020.118510","journal-title":"Life Sci"},{"key":"2169_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02440-y","volume":"18","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020c) Remdesivir versus ritonavir\/lopinavir in COVID-19 patients. Ir J Med Sci 18:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02440-y","journal-title":"Ir J Med Sci"},{"key":"2169_CR35","doi-asserted-by":"publisher","unstructured":"Vitiello A, Ferrara F (2021a) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med 178:106322, ISSN 0954-6111, https:\/\/doi.org\/10.1016\/j.rmed.2021.106322","DOI":"10.1016\/j.rmed.2021.106322"},{"issue":"156","key":"2169_CR36","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.ejps.2020.105579","volume":"1","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021b) Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci 1(156):105579. https:\/\/doi.org\/10.1016\/j.ejps.2020.105579","journal-title":"Eur J Pharm Sci"},{"key":"2169_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02584-5","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Porta R, Pianesi L, Ferrara F (2021a) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-021-02584-5","journal-title":"Ir J Med Sci"},{"key":"2169_CR38","doi-asserted-by":"publisher","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V, Ferrara F (2021b) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol ISSN 0198-8859, https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007","DOI":"10.1016\/j.humimm.2021.01.007"},{"key":"2169_CR39","doi-asserted-by":"publisher","unstructured":"Vitiello A, Pelliccia C, Ferrara F (2021c) Drugs acting on the renin\u2013angiotensin system and SARS-CoV-2. Drug Discov Today ISSN 1359-6446, https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010","DOI":"10.1016\/j.drudis.2021.01.010"},{"key":"2169_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43066-021-00082-y","volume":"11","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V et al (2021d) The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver Journal 11:11. https:\/\/doi.org\/10.1186\/s43066-021-00082-y","journal-title":"Egypt Liver Journal"},{"key":"2169_CR41","doi-asserted-by":"crossref","unstructured":"Vitiello A, La Porta R, Ferrara F (2021e) Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 110486,ISSN 0306-9877","DOI":"10.1016\/j.mehy.2021.110486"},{"key":"2169_CR42","doi-asserted-by":"publisher","unstructured":"Vitiello A, Ferrara F, La Porta R Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Received: 9 December 2020 \/Accepted: 16 December 2020 Irish Journal of Medical Science (1971 -) https:\/\/doi.org\/10.1007\/s11845-020-02482-2","DOI":"10.1007\/s11845-020-02482-2"},{"key":"2169_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473","journal-title":"Lancet"},{"key":"2169_CR44","unstructured":"World health organization (WHO) https:\/\/www.who.int\/emergencies\/diseases\/novel coronavirus2019\/situation-reports (Situation Reports March 2021)"},{"issue":"2020","key":"2169_CR45","first-page":"727","volume":"382","author":"N Zhu","year":"2019","unstructured":"Zhu N et al (2019) A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(2020):727\u2013733","journal-title":"N Engl J Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-021-02169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T06:02:40Z","timestamp":1640930560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-021-02169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s00210-021-02169-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}